Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 9 of 22 for:    capsule | Recruiting Studies | fecal microbiota transplantation

Fecal Microbiota Transplantation for Eradication of CRE

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03167398
Recruitment Status : Recruiting
First Posted : May 30, 2017
Last Update Posted : September 3, 2018
Sponsor:
Collaborator:
Tel-Aviv Sourasky Medical Center
Information provided by (Responsible Party):
Rambam Health Care Campus

Brief Summary:

Antibiotic resistance has emerged world wide and is of major concern. Multi-drug resistant (MDR) bacteria is widely spread and is now a major factor in morbidity and mortality in health-care settings. Among MDRs, carbapenem-resistant Enterobacteriaceae (CRE) are of special concern, receiving the highest classification of "urgent threat level" in the US President Report. Consistent mortality rates of 40-50% are observed among inpatients with infections caused by CRE in hospitals worldwide, related mainly to unavailable, delayed or ineffective antibiotic treatment options.

The extremely high mortality rates of patients with CRE infections have driven efforts to prevent the acquisition and spread of these bacteria in hospitals. These include screening for carriage, contact isolation of carriers, cohorting, dedicated healthcare staff and other infection control measures. These strategies have been proven as effective but are cumbersome and expensive. In most locations these strategies failed to completely eradicate CRE endemicity.

CRE decolonization (eradication of colonization) might offer a double benefit - reducing the risk for the individual carrier to develop an infection due to the resistant strain (by that, potentially lowering the mortality risk) and preventing the bacteria from spreading to other patients, exposing them to the same hazard.

Fecal microbiota transplantation (FMT), in which fecal material enriched with commensal microorganisms is transferred from a healthy donor, have proven efficacy in the treatment of recurrent Clostridium difficile infection (CDI) in multiple trails. Major adverse events that has been reported so far are mostly related to the route of administration (aspiration during nasogastric tube administration/colonoscopy). Other adverse events include mostly GI related symptoms (diarrhea, nausea, belching) and are self limited and resolve in few hours. FMT seems to be safe and effective both in immunocompetent and immunocompromised patients.

The high efficacy of FMT in the treatment of a multi-drug resistant pathogen such as Clostridium difficile, suggest that it might be an efficient tool for other MDR pathogens (e.g. CRE).

The authors aim to assess the effects of FMT on colonization and clinical infections with CRE. The potential of FMT to restore the gut microbiome and compete with residual resistant strains offer a novel way to fight the current MDR epidemic.

The authors will apply FMT on a cohort of CRE carriers in a single center in Israel. FMT will be given by capsules for 2 consecutive days followed by rectal sampling at predefined timepoint in the following 6 months.


Condition or disease Intervention/treatment Phase
Antibiotic Resistant Strain Microbial Colonization Other: Fecal Microbiota Transplantation Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Fecal Microbiota Transplantation for Eradication of Carbapenem-resistant Enterobacteriaceae Colonization
Actual Study Start Date : February 1, 2018
Estimated Primary Completion Date : March 30, 2019
Estimated Study Completion Date : October 30, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Bowel Movement

Arm Intervention/treatment
Experimental: CRE carriers
Fecal Microbiota Transplantation
Other: Fecal Microbiota Transplantation
Patients able to swallow will be given capsulized FMT using 15 capsules a day for two consecutive days. Patients will be treated concomitantly with omeprazole 20mg once in the evening before FMT and daily for the next 2 days.




Primary Outcome Measures :
  1. CRE eradication on rectal stool samples [ Time Frame: 1 month after intervention ]
    3 consecutive negative rectal samples for CRE



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adult inpatients ≥18 years positive for CRE of any strain and resistance mechanism in rectal surveillance stool samples, with or without CRE clinical samples. A positive rectal swab within one week before randomization will be mandatory.

Exclusion Criteria:

  • Pregnant women
  • Patients with severe neutropenia (<100/µl)
  • Surgical patients with perfurated viscous

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03167398


Contacts
Layout table for location contacts
Contact: Haggai Bar-Yoseph, MD +972-4-7771758 h_bar-yoseph@rambam.gov.il

Locations
Layout table for location information
Israel
Rambam Health Care Campus Recruiting
Haifa, Israel
Contact: Haggai Bar-Yoseph, MD    +972-4-7771758    h_bar-yoseph@rambam.gov.il   
Sponsors and Collaborators
Rambam Health Care Campus
Tel-Aviv Sourasky Medical Center

Layout table for additonal information
Responsible Party: Rambam Health Care Campus
ClinicalTrials.gov Identifier: NCT03167398     History of Changes
Other Study ID Numbers: 0215-17-RMB-CTIL
First Posted: May 30, 2017    Key Record Dates
Last Update Posted: September 3, 2018
Last Verified: August 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Rambam Health Care Campus:
fecal microbiota transplantation
carbapenem-resistant enterobacteriaceae
multidrug resistant bacteria
carrier
Additional relevant MeSH terms:
Layout table for MeSH terms
Communicable Diseases
Infection